FDA approves packaging for Bracco's Lumason agent

AuntMinnie.com staff writers

Feb 21, 2021

2020 10 16 23 20 7849 Bracco2 Rsna 2018 400

Bracco is set to introduce a 20-vial package of its Lumason ultrasound contrast agent following clearance by the U.S. Food and Drug Administration (FDA).

The new packaging of Lumason (sulfur hexafluoride lipid-type A microspheres) contrast is a good option for the environmentally conscious and better from the point of view of storage space, according to the company. Each vial contains 25 mg of lipid-type A lyophilized powder and 60.7 mg of sulfur hexafluoride headspace, and a Mini-Spike dispensing pin.

Ultrasound Diagnostic Control Panel 400

Ultrasound falls short for detecting endometrial cancer in Black women

February 21, 2025

1Each lung has been split into three parts. Each area has been given a score between 0 and 3. Score values are shown in Ultrasonograms to match 4 different patterns. During a longitudinal scan with a high-resolution linear probe, pictures of patterns were taken. The scores are as follows: 0 means A pattern, 1 means B pattern, 2 means severe B pattern, and 3 means extended consolidation. Images available for publishing under a creative commons license, CC BY-NC-ND 4.0.

LUS reliable for care strategies in infants with RDS

February 20, 2025

2025 02 19 Ajr Lung Images Thumbnail

Lung biomarkers inform patient selection for EBUS-TBNA

February 19, 2025

Ultrasound rules out N2 disease in PET-negative lung cancer patients

February 12, 2025

Ultrasound falls short for detecting endometrial cancer in Black women

By Amerigo Allegretto

Ultrasound-based strategies fall short of biopsy for detecting endometrial cancer in non-Hispanic Black women.

February 21, 2025

Ultrasound Diagnostic Control Panel 400

LUS reliable for care strategies in infants with RDS

By Amerigo Allegretto

Lung ultrasound (LUS) scoring is reliable for determining whether preterm newborns need surfactant for suspected respiratory distress syndrome (RDS).

February 20, 2025

1Each lung has been split into three parts. Each area has been given a score between 0 and 3. Score values are shown in Ultrasonograms to match 4 different patterns. During a longitudinal scan with a high-resolution linear probe, pictures of patterns were taken. The scores are as follows: 0 means A pattern, 1 means B pattern, 2 means severe B pattern, and 3 means extended consolidation. Images available for publishing under a creative commons license, CC BY-NC-ND 4.0.

Lung biomarkers inform patient selection for EBUS-TBNA

By Amerigo Allegretto

Lung imaging biomarkers can inform patient selection for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

February 19, 2025

2025 02 19 Ajr Lung Images Thumbnail

Ultrasound rules out N2 disease in PET-negative lung cancer patients

By Amerigo Allegretto

Combined endobronchial ultrasound and endoscopic ultrasound is a reliable tool for ruling out N2 disease in PET-negative lung cancer patients.

February 12, 2025

Cryoablation leads to low breast cancer recurrence rates

By Amerigo Allegretto

Ultrasound-guided cryoablation can be considered for breast cancer patients who are poor surgical candidates or who refuse surgery.

February 7, 2025

Ultrasound, histopathological diagnoses assess benign breast lesions

By Amerigo Allegretto

Sonographic imaging descriptors and histopathological diagnoses are needed for more accurate assessment of benign breast lesions.

February 3, 2025

Ultrasound Breast 400

AI assistance improves CHD detection on prenatal ultrasound

By Amerigo Allegretto

AI boosts detection of major congenital heart defects (CHDs) on prenatal ultrasound, suggest findings presented at the Annual Pregnancy Meeting of the SMFM.

January 31, 2025

Smfm Ultrasound Ai Fetal Thumbnail

LI-RADS ultrasound surveillance version 2024 improves HCC detection

By Amerigo Allegretto

The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.

January 22, 2025

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

CEUS resolves indeterminate CT, MRI liver observations

By Amerigo Allegretto

Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

POCUS useful for diagnosis of retained conception tissue

By Amerigo Allegretto

Point-of-care ultrasound (POCUS) can be a useful tool for diagnosing the presence of retained conception tissue.

January 15, 2025

Ultrasound Portable

AI guidance leads to better LUS image acquisition by novice users

By Amerigo Allegretto

Healthcare professionals who are not sonography experts can successfully acquire lung ultrasound (LUS) images with AI assistance.

January 15, 2025

Ultrasound Probe2 Social

Ultrasound ablation is effective for treating hyperparathyroidism

By Amerigo Allegretto

Ultrasound-guided thermal ablation techniques are safe and effective in treating patients with secondary hyperparathyroidism.

January 7, 2025

Ultrasound images depict a 63-year-old man who underwent radiofrequency ablation (RFA) for the treatment of secondary hyperparathyroidism. (A–D) 2D images show four hyperplastic parathyroid glands on the right and left sides (marked with crosshairs). The numbers near the crosshairs represent the number of measured trails. (E) Ultrasound-guided infusion of isolation fluid (arrowheads) around the hyperplastic parathyroid gland to protect vital organs such as the trachea (Tr), carotid arteries (CA), and recurrent laryngeal nerve pathway area (arrow). F) Ultrasound-guided RFA of the hyperplastic parathyroid gland. (G) Immediate postoperative contrast-enhanced ultrasound shows no contrast enhancement in the ablation area. The ablation procedures for the other three parathyroid glands were the same as those described above. Image courtesy of the RSNA,

Page 1 of 513